Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Tempest Therapeutics Q1 EPS $(3.16) Beats $(3.71) Estimate

Author: Benzinga Newsdesk | May 13, 2025 03:45pm
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(3.16) per share which beat the analyst consensus estimate of $(3.71) by 14.82 percent. This is a 31.6 percent increase over losses of $(4.62) per share from the same period last year.

Posted In: TPST


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist